- Silo Pharma Inc SILO has announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease (AD).
- The research was conducted as part of a sponsored research agreement with Columbia University in New York.
- Silo Pharma's Commercial Evaluation License Agreement (CELA) with Columbia University grants an option to license two investigational assets - SPC-14 targeting Alzheimer's disease and SPC-15 targeting stress-induced affective disorders.
- SPC-14 combines an FDA-approved therapeutic with ketamine. It is in development for dementia related to Alzheimer's disease.
- Initial data from its SPC-14 research studies show that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.
- "The result from these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer's," said Eric Weisblum, Chief Executive Officer of Silo Pharma...We believe SPC-14 should be eligible for development under the FDA's 505(b)(2) regulatory pathway. This will allow Silo Pharma to reach efficacy clinical trials faster and save costs."
- Earlier this week, Columbia University granted Silo an extension for its option to license certain assets currently under development, including Alzheimer's disease and Stress-Induced Anxiety.
- Price Action: SILO shares closed at $4.78 on Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.